The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia

Circ J. 2008 Oct;72(10):1576-82. doi: 10.1253/circj.cj-08-0095. Epub 2008 Aug 29.

Abstract

Background: Several epidemiologic studies in Japan have shown the risk factors for coronary heart disease (CHD) in the general population. The present analysis determined the risk factors for CHD in the MEGA Study, a large primary prevention trial with pravastatin in Japanese with hypercholesterolemia.

Methods and results: The relationship between each baseline characteristic and the risk of CHD for the 5-year study period were evaluated using the Cox proportional hazard model. The multivariable predictors of CHD were sex, age, high-density lipoprotein-cholesterol (HDL-C), diabetes mellitus (DM), hypertension (HT), and history of smoking. Serum total and low-density lipoprotein-cholesterol were not independent risk factors for CHD in the current analysis. In addition, the effect of pravastatin was evaluated by subgroups in each risk factor using the interaction in a Cox model. Diet plus pravastatin treatment reduced CHD risk by 14-43% compared with diet alone, regardless of the presence or absence of risk factors.

Conclusions: The risk factors for CHD were sex, age, DM, HT, smoking, and low HDL-C in the MEGA Study. The pravastatin treatment was effective for reducing the risk of CHD, regardless of the presence of risk factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alcohol Drinking / adverse effects
  • Cholesterol, HDL / blood
  • Coronary Disease / drug therapy*
  • Coronary Disease / epidemiology*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / complications*
  • Hypercholesterolemia / drug therapy*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pravastatin / therapeutic use*
  • Risk Assessment
  • Risk Factors
  • Smoking / adverse effects

Substances

  • Cholesterol, HDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pravastatin